Prostate cancer Board decisions

The Board granted a 100 percent evaluation for prostate cancer and established basic eligibility for Dependents' Educational Assistance under 38 USC Chapter 35.

The Board denied the claims for an initial rating in excess of 10 percent for bilateral hearing loss, service connection for right and left shoulder disabilities, and remanded the claim for entitlement to service connection for prostate cancer. The Board also denied a total disability rating based on individual unemployability (TDIU).

The Board denied service connection for bilateral hearing loss and remanded claims for left eye glaucoma, right hip arthritis, prostate cancer, a right foot disability, urticaria, chronic pain of the bilateral lower extremities, diabetes mellitus, type 2 (DMII), and trigeminal neuralgia.

The Board denied service connection for prostate cancer and erectile dysfunction, finding no evidence linking the disabilities to the Veteran's active service.

The Board granted a 40 percent disability rating for residuals of prostate cancer status post radical prostatectomy, as the Veteran's symptoms most closely approximate those required for that rating.

The Board remands the claim for a direct service connection for prostate cancer to obtain an adequate medical opinion.

The Board remands the issues of whether the discontinuance of the 100 percent disability rating for prostate cancer as of March 1, 2025 was proper and entitlement to an initial disability rating for prostate cancer in excess of 30 percent on and after March 1, 2025.

The Board denied service connection for prostate cancer, finding that the Veteran's condition did not onset in and is not the result of active service, including exposure to contaminated water at Camp Lejeune.

The Board granted service connection for diabetes mellitus, type II, hypertension, and prostate cancer as due to exposure to herbicides. It also granted service connection for erectile dysfunction, nephropathy, bilateral lower extremity peripheral neuropathy, bilateral upper extremity peripheral neuropathy, and diabetic retinopathy as secondary to the already service-connected conditions of diabetes mellitus or prostate cancer.

The Board denied the veteran's claims for increased ratings and service connection, finding no evidence to support higher ratings or a link between his claimed conditions and military service.

The Board remands the claim for service connection for prostate cancer due to various theories, including exposure to herbicides in Okinawa, Camp Lejeune's contaminated water supply, and fuel and exhaust fumes from the Veteran's motor vehicle operator MOS.

The Board granted an earlier effective date of June 6, 2023 for service connection for prostate cancer and an initial rating of 30 percent for tension headaches.

The appeal for service connection for prostate cancer was withdrawn by the Veteran and therefore dismissed.

The Board remands the case to correct pre-decisional duty to assist errors related to asbestos and herbicide exposure claims.

The Board granted earlier effective dates of December 21, 2021, for the awards of service connection for prostate cancer with urinary frequency, erectile dysfunction, and special monthly compensation based on loss of use of creative organ.

The Board granted service connection for diabetes mellitus type 2 and prostate cancer, finding a causal relationship between the Veteran's in-service exposure to defoliant agents and these conditions.

The Board remands the case for a new medical opinion to determine if the Veteran's prostate cancer was caused or aggravated by his service-connected GERD, specifically the medication he took for it.

The appeal for entitlement to service connection for prostate cancer residuals and compensation benefits under 38 U.S.C. § 1151 for VA medical care related to the Veteran's prostate cancer treatment was dismissed due to procedural defects.

The Board remands the issue of entitlement to service connection for prostate cancer, including as secondary to ionizing radiation exposure, for further development and clarification.

The Board denied the veteran's appeal for an earlier effective date prior to August 10, 2022, for service connection of prostate cancer.